Company
Dr Reddys Labs SA
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
13
9 still marketed
Novel approvals
0
Approvals since 2021
4
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Zimrixby approved OrphanJul 31, 2026
- Phenylephrine Hydrochloride In 0.9% Sodium Chloride approved May 30, 2025
- Rezipres approved Jun 14, 2021
- Biorphen new use Mar 11, 2021
- Cyclophosphamide approved Jul 30, 2020
- Biorphen approved Oct 21, 2019
- Bortezomib approved Oct 4, 2019
- Amvaz approved Oct 31, 2003
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (9)
Newest FDA action first.
- Zimrixby Rituximab-Cdxx · 2026
- Phenylephrine Hydrochloride In 0.9% Sodium Chloride Phenylephrine Hydrochloride · 2025
- Cyclophosphamide Cyclophosphamide · 2020
- Biorphen Phenylephrine Hydrochloride · 2019
- Tri-Norinyl 28-Day Ethinyl Estradiol, Norethindrone · 1984
- Habitrol Nicotine · 1991
- Eryc Erythromycin · 1981
- Trimethoprim Trimethoprim · 1982
- Ssd Af Silver Sulfadiazine · 1982
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.